Use of Trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of CD9, Akt and molecules of the tetraspanin signalling network
The present invention consists in a method for the diagnosis and treatment of cancer characterized by the fact that an increase in the levels of Trop-2 in the tumor, as compared to the levels of Trop-2 in the corresponding normal tissues, constitutes a biological marker that can predict the tumor response to anticancer therapy with drugs directed against components of the signalling network of Trop- 2, including but not limited to drugs which inhibit CD9, Akt and molecules of the tetraspanin signalling network. More particularly, the invention concerns the use of the biological marker Trop-2 in the screening of new compounds, and in the clinical setting as an indicator for the use of anticancer drugs targeted against molecules of the signalling network of Trop-2, including but not limited to drugs that inhibit CD9, Akt and molecules of the tetraspanin signalling network.
